Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

Sep 18, 2023

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

Sep 11, 2023

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Sep 5, 2023

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

Aug 14, 2023

Cellectar Provides a Research and Development Program Summary

Jun 12, 2023

UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023

Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

Mar 9, 2023

Cellectar to Participate at Upcoming Banking Conferences

Mar 8, 2023

Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient

Feb 28, 2023